Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
Date:11/3/2008

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its Phase I and Phase II U.K. combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials for patients with advanced cancers. The principal investigator for the trial is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

The results were presented at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

"The most striking finding," said George M. Gill, MD, Oncolytic's Senior VP of Clinical and Regulatory Affairs, "is that in nine evaluable late-stage head and neck cancer patients, eight of whom have refractory disease, four had durable partial responses and four others showed stable disease for periods of two, five plus, and eight cycles."

Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response. These results appear to confirm preclinical evidence of synergy for REOLYSIN(R) and platinum/taxane combinations. A U.S. Phase 2 trial has now been opened in this patient population utilizing this regimen.

Fourteen patients have been treated to date in the Phase I and Phase II (REO 011) trials. The detailed results are summarized in the following table:

-------------------------------------------------------------------------

REOLYSIN

Primary Tumour Dose TCID(50) Cycles Best Response

-------------------------------------------------------------------------

Phase I patients

-------------------------------------------------------------------------

Melanoma 3x10(9) 2 PD

-------------------------------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/12/2014)... New York (PRWEB) July 12, 2014 ... analysis for various reagents used in the ... is driving the life science reagents market ... study include manufacturers and providers of life ... Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , ...
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3
... blood, termed ,endometrial regenerative cells, (ERCs) are capable ... of advanced peripheral artery disease. A study published ... Translational Medicine demonstrates that when circulation-blocked mice were ... restored. , Critical limb ischemia, an ...
... SAN JOSE, Calif., Aug. 18 VNUS(R) Medical,Technologies, ... quarter results and,revises its full year 2008 guidance. ... operating expenses and certain balance sheet accounts,to record ... appropriately recorded in prior periods since the adoption ...
... (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company,focused on ... ended June 30, 2008., Net loss was $3.8 ... June 30, 2008, compared to $0.5 million, or $0.05 ... was $7.5 million, or $0.65 per share, for the,six ...
Cached Biology Technology:Limbs saved by menstrual blood stem cells 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 2VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 3VNUS Corrects Second Quarter 2008 Results and Revises Full Year 2008 Guidance 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 2Arno Therapeutics Announces Second Quarter 2008 Financial Results 3Arno Therapeutics Announces Second Quarter 2008 Financial Results 4Arno Therapeutics Announces Second Quarter 2008 Financial Results 5
(Date:7/14/2014)... to the discovery and description of Rhipidocyrtus muiri ... turned out to represent a new genus and species. The ... from Borneo is discussed in a recent paper published in ... The holotype male, and only known specimen of Rhipidocyrtus ... subsequent to this it was transferred among several researchers in ...
(Date:7/14/2014)... consequence of aging? , Although it is widely thought ... risk of developing several common cancers decreases with age. ... decrease with age in the risk of developing certain ... puzzle was presented in a recent paper published in ... P. Brody of the Department of Biomedical Engineering at ...
(Date:7/13/2014)... A new study in women suggests that experiencing one ... single high-fat meal can slow the body,s metabolism, potentially ... about the previous day,s stressors before giving them a ... fat. The scientists then measured their metabolic rate ... and fat and took measures of blood sugar, ...
Breaking Biology News(10 mins):Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... the most common childhood cancer is cured in about ... number was closer to five percent. In efforts to ... Children's Research Hospital, the University of Tennessee, and the ... play a role in the effectiveness of chemotherapy drugs. ...
... nanotubes make an ideal scaffold for the growth of bone ... broken bones, allowing them to simply inject a solution of ... appears in the June 14 issue of the American Chemical ... scientific society. , The success of a bone graft depends ...
... primordial soup that produced life on earth, there were ... acid chains, which were the first elements able to ... these molecules were ribonucleic acid (RNA) chains, a molecule ... has the secondary role in cells of copying information ...
Cached Biology News:Genes linked to treatment resistance in children with leukemia 2Nanotubes inspire new technique for healing broken bones 2Nanotubes inspire new technique for healing broken bones 3Life's origins were easier than was thought 2
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
... 9001:2000 Certified USDA Research Registered OLAW Assured ... Training AALAS Certified Technicians Documentation ... Documentation Upon Request Focus CRP ... all your custom immunology service needs. ...
... BalanceTalk XL provides balance data collection and ... Complete integration with Microsoft Excel , ... moisture analyzers , New balances can be added ... Collect data from multiple balances into one spreadsheet ...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Biology Products: